Document is current
Any future updates will be listed below
-
Authors
Rädler, Patrick D.
Wehde, Barbara L.
Triplett, Aleata A.
Shrestha, Hridaya
Shepherd, Jonathan H. https://orcid.org/0000-0001-6322-6347
Pfefferle, Adam D.
Rui, Hallgeir https://orcid.org/0000-0002-8778-261X
Cardiff, Robert D.
Perou, Charles M.
Wagner, Kay-Uwe https://orcid.org/0000-0002-5081-0226
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA009476, CA228326, CA14876, CA58223, CA117930, CA202917, CA022453)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Breast Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
METAvivor
- License Information
-
More Information
Article History
Received: 4 September 2020
Accepted: 21 May 2021
First Online: 18 June 2021
Competing interests
: C.M.P. is an equity stockholder and consultant of BioClassifier LLC; C.M.P. has also listed an inventor on patent applications for the Breast PAM50 Subtyping assay. The remaining authors declare no competing interests.
